glp-1 obesity drug updates Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine Transforming obesity: The advancement of

Gastrointestinal events were the most common adverse events in both groups and generally occurred during dose escalation

Very recently, GLP1 monotherapies have also been applied in the pharmacological management of PCOS, with promising results 32 , which are yet to be consolidated in clinical practice

Our attorneys have recovered over $900 million in compensation for our valued clients since 2000 alone (see disclaimer below), and were proud to be named a Best Family-Run Law Firm in 2025 by NC Lawyers Weekly

By balancing the potential benefits and risks of treatment using evidence-based strategies, HCPs are well placed to help optimise the use of GLP-1 RAs in the management of obesity and overweight

Wang SY, Wu SL, Chen TC, Chuang CS

For example, ongoing research aims to identify new analogs or formulations of GLP-1 that may offer improved dosing regimens, reduced side effects, or enhanced efficacy